CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AliveDx Suisse S.A. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AliveDx Suisse S.A.
B1, Business Park Terre Bonne,
Route de Crassier 13, Eysins
Phone: +41 227169800p:+41 227169800 1262  Switzerland
Emerged from Bankruptcy on 2/16/2023
This company ceased filing statements with the SEC on 6/30/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
AliveDx Suisse S.A., previously known as Quotient Limited, is a Switzerland-based diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Additionally The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20223/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Manuel O.Mendez Muniz 54 4/1/2021 4/1/2021
Chief Financial Officer AliKiboro 47 12/1/2021 12/1/2021
Head of Finance & Group Controller VittoriaBonasso 46 2/1/2021 2/1/2021
Chief Commercial Officer MohammadEl Khoury 62 10/5/2021 10/5/2021
Director BradleyMeyer 2/16/2023 2/16/2023

Subsidiaries
Business Name Address City State/Province Country
Quotient Suisse SA Unit B1, Terre Bonne Business park Eysins 1262 Switzerland
Alba Bioscience, Inc. 301 South State Street Newtown PA United States
Alba Bioscience Limited 5 James Hamilton Way Milton Bridge Penicuik United Kingdom
Quotient Biocampus Limited 5 James Hamilton Way Penicuik Scotland United Kingdom

Business Names
Business Name
Alba Bioscience Limited
QBD (QS IP) Limited
QBD (QS-IP) Limited
7 additional Business Names available in full report.

General Information
Outstanding Shares: 4,035,013 (As of 2/2/2023)
Shareholders: 16
Stock Exchange: OTC
Federal Tax Id: 264719797


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 11, 2024